Abstract It is widely appreciated that early detection is the key to making inroads in the fight against cancers. Like most cancers, colorectal cancers (CRCs) express tumor antigens that can induce humoral immune response. The identification of the autoantibodies against tumor antigens may facilitate early diagnosis of CRC. In this application, we propose to screen sera from newly diagnosed colon cancer patients on an innovative protein microarray platform to determine seroreactivity to>2000 individual antigens with a focus on antigens that were shown to express differentially in CRC and healthy controls to identify an autoantibody panel and a combination rule that can distinguish CRC from healthy controls. This is a collaborative project between the LaBaer lab (EDRN) and the Liebler lab (CPTAC).
|Effective start/end date||1/1/14 → 8/31/15|
- HHS-NIH: National Cancer Institute (NCI): $154,500.00
Protein Array Analysis
Early Detection of Cancer